Skip to main content

Table 3 Total Fatty acid profile of HCV patients (pre and post) in comparison of controls

From: A comparative study of serum lipid contents in pre and post IFN-alpha treated acute hepatitis C patients

Fatty acids Controls HCV pretreatment patients HCV post treatment patients
C – 14:0 1.1 ± 3.2a 2.8 ± 1.7b 1.9 ± 0.7c
C - 16 : 0 23.9 ± 5.3a 26.6 ± 3.8b 27.8 ± 2.3c
C - 18 : 0 14.7 ± 5.4 15.4 ± 5.12 12.3 ± 3.1
C - 20 : 0 0.4 ± 1.1 0.3 ± 0.9 0.4 ± 0.8
C - 14 : 1 0.5 ± 0.9 0.3 ± 2.2 0.4 ± 0.4
C - 16 : 1 2.6 ± 2.2 3.2 ± 1.4 3.8 ± 1.1
C - 18 : 1 19.8 ± 4.6 19.6 ± 3.6 20.9 ± 1.8
C - 22 : 1 1.9 ± 1.4 2.7 ± 1.4 2.3 ± 0.8
C – 24 : 1 0.3 ± 0.7 ND ND
C - 18 : 2 25.0 ± 5.4a 20.9 ± 5.8b 21.6 ± 4.1c
C - 18 : 3 0.8 ± 1.3 0.3 ± 1.0 0.7 ± 0.9
C - 20 : 4 5.9 ± 2.1 5.1 ± 1.6 5.3 ± 0.8
C - 20 : 5 0.9 ± 1.7 0.6 ± 1.3 0.5 ± 0.9
C - 20 : 3 0.4 ± 0.6 0.2 ± 0.9 ND
C - 22 : 6 0.39 ± 0.7 ND ND
C-18:1: C-18:0 1.3 1.3 1.7
C-16:1: C-16:0 0.1 0.2 0.3
PUFA: SFA 1.0 0.6 0.8
  1. Values represent mean ± Standard deviation of triplicates. Different alphabets on the same row indicate significant difference at p <0.05. myristic acid (C14:0), myristoleic acid (C14:1), palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0), oleic acid (C18:1), linoleic acid (C18:2), α-linolenic acid (C18:3), arachidic acid (C20:0), eicosatrienoic acid (C-20:3), arachidonic acid (C20:4), eicosapentaenoic acid (EPA (C20:5), docosenoic acid (C22:1), docosahexaenoic acid (DHA (C22:6), nervonic acid(C24:1), not detected (ND)